Last $6.02 USD
Change Today +0.094 / 1.59%
Volume 100.0K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 12:07 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$5.99
Previous Close
$5.93
Day High
$6.04
Day Low
$5.96
52 Week High
09/13/13 - $9.89
52 Week Low
05/9/14 - $4.56
Market Cap
204.2M
Average Volume 10 Days
198.6K
EPS TTM
$-1.87
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer and Vice President
Total Annual Compensation: $190.6K
President of Progenitor Cell Therapy, LLC and...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Presents at Global Online CEO Conference, Jul-16-2014 12:30 PM

Neostem, Inc. Presents at Global Online CEO Conference, Jul-16-2014 12:30 PM.

Neostem, Inc. Appoints Steven M. Klosk as Independent Member of Board of Directors

Effective as of July 8, 2014, Neostem, Inc. appointed Steven M. Klosk, age 57, to serve as an independent member of the company's board of directors. Since 2008, Mr. Klosk has served as President, CEO & Director at Cambrex Corporation. In his current role, he is responsible for all aspects of Cambrex’s global business with manufacturing and R&D facilities in the US, Sweden, Italy, Estonia, Germany and India. Mr. Klosk has also held other executive positions at Cambrex Corporation, including Executive Vice President & COO; as well as President, Pharma Business Unit from 2007 through 2008, which encompassed four operating units in North America and Europe.

Neostem, Inc.(NasdaqCM:NBS) added to Russell 2000 Index

Neostem, Inc. will be added to the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $6.02 USD +0.094

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.09 USD +0.0046
Athersys Inc $1.59 USD +0.0682
BioTime Inc $2.77 USD +0.1155
Cytori Therapeutics Inc $2.11 USD +0.039
Fibrocell Science Inc $3.09 USD +0.02
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.